{"id":"il-17a-antibody","safety":{"commonSideEffects":[{"rate":"10%","effect":"Nausea"},{"rate":"8%","effect":"Headache"},{"rate":"5%","effect":"Injection site reaction"}]},"_chembl":{"chemblId":"CHEMBL6042642","moleculeType":null,"molecularWeight":"381.27"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"IL-17A is a pro-inflammatory cytokine, and blocking its action can reduce inflammation in various conditions.","oneSentence":"IL-17A antibody targets the IL-17A receptor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:35:19.245Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Psoriasis"},{"name":"Plaque psoriasis"}]},"trialDetails":[{"nctId":"NCT07498634","phase":"PHASE3","title":"Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active AS","status":"COMPLETED","sponsor":"Zhejiang Kanova Biopharmaceutical Co., LTD","startDate":"2023-09-21","conditions":"Phase III","enrollment":323},{"nctId":"NCT06945107","phase":"PHASE3","title":"A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.","startDate":"2025-05-27","conditions":"Plaque Psoriasis","enrollment":308},{"nctId":"NCT07485764","phase":"PHASE4","title":"Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-06","conditions":"Psoriasis, Plaque Psoriasis, Moderate-to-severe Plaque Psoriasis","enrollment":186},{"nctId":"NCT07489573","phase":"PHASE4","title":"Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-08-21","conditions":"Hidradenitis Suppurativa (HS)","enrollment":36},{"nctId":"NCT07449156","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Huaota Biopharmaceutical Co., Ltd.","startDate":"2026-03-27","conditions":"Acne Vulgaris","enrollment":21},{"nctId":"NCT07443956","phase":"NA","title":"Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis","status":"NOT_YET_RECRUITING","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2026-02-24","conditions":"Psoriatic Arthritis (PsA), Obesity & Overweight","enrollment":45},{"nctId":"NCT06895499","phase":"PHASE1, PHASE2","title":"Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.","status":"RECRUITING","sponsor":"Shanghai Huaota Biopharmaceutical Co., Ltd.","startDate":"2025-03-19","conditions":"Hidradenitis Suppurativa","enrollment":15},{"nctId":"NCT05975268","phase":"PHASE3","title":"A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-08-28","conditions":"Moderate to Severe Chronic Plaque Psoriasis","enrollment":747},{"nctId":"NCT07244510","phase":"PHASE2","title":"Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa","status":"NOT_YET_RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2025-11-18","conditions":"Hidradenitis Suppurativa (HS)","enrollment":60},{"nctId":"NCT06336343","phase":"PHASE4","title":"Bimekizumab in Plaque Psoriasis","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2024-06-03","conditions":"Plaque Psoriasis","enrollment":60},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT03447704","phase":"PHASE3","title":"International Multicenter Comparative Randomized Placebo-controlled Clinical Study of Efficacy and Safety of BCD-085 in Patients With Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Biocad","startDate":"2018-02-09","conditions":"Ankylosing Spondylitis","enrollment":228},{"nctId":"NCT03598751","phase":"PHASE3","title":"Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis","status":"COMPLETED","sponsor":"Biocad","startDate":"2018-07-25","conditions":"Psoriatic Arthritis","enrollment":194},{"nctId":"NCT06999083","phase":"PHASE1","title":"A Study to Evaluate Single-dose of HB0043 in Healthy Adult Participants","status":"RECRUITING","sponsor":"Shanghai Huaota Biopharmaceutical Co., Ltd.","startDate":"2025-06-03","conditions":"Healthy","enrollment":52},{"nctId":"NCT04979910","phase":"PHASE2","title":"Targeting IL-17A for Treatment-Resistant Depression","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2021-08-27","conditions":"Major Depressive Disorder","enrollment":7},{"nctId":"NCT05377944","phase":"PHASE3","title":"Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2022-10-26","conditions":"Plaque Psoriasis","enrollment":502},{"nctId":"NCT03331835","phase":"PHASE4","title":"A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2017-11-03","conditions":"Psoriasis Vulgaris","enrollment":210},{"nctId":"NCT05536726","phase":"PHASE3","title":"A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2023-01-07","conditions":"Psoriasis","enrollment":458},{"nctId":"NCT06833112","phase":"PHASE4","title":"Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital Of Guizhou Medical University","startDate":"2025-02","conditions":"Ankylosing Spondylitis","enrollment":10},{"nctId":"NCT06802848","phase":"","title":"Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)","status":"NOT_YET_RECRUITING","sponsor":"Chongqing Genrix Biopharmaceutical Co., Ltd","startDate":"2025-01-30","conditions":"Plaque Psoriasis, Psoriatic Arthritis, Scalp Psoriasis","enrollment":1000},{"nctId":"NCT06380907","phase":"PHASE2","title":"A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis","status":"RECRUITING","sponsor":"Zai Lab (Hong Kong), Ltd.","startDate":"2024-05-22","conditions":"Plaque Psoriasis","enrollment":250},{"nctId":"NCT06302556","phase":"","title":"The Role of Immune Checkpoints in Lung Transplant (ILTRA)","status":"UNKNOWN","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2024-04","conditions":"Lung Transplant Rejection","enrollment":280},{"nctId":"NCT06299982","phase":"PHASE3","title":"An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO","status":"UNKNOWN","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2024-05-15","conditions":"Plaque Psoriasis Patients","enrollment":750},{"nctId":"NCT06250062","phase":"PHASE2","title":"A Clinical Study of JS005 in Patients With Ankylosing Spondylitis","status":"UNKNOWN","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2024-01-12","conditions":"Ankylosing Spondylitis","enrollment":261},{"nctId":"NCT06197009","phase":"PHASE2","title":"Efficacy and Safety of SCT650C in Participants With Axial Spondyloarthritis","status":"NOT_YET_RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2024-07-01","conditions":"Axial Spondyloarthritis","enrollment":168},{"nctId":"NCT06110676","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of LZM012","status":"UNKNOWN","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2023-08-21","conditions":"Psoriasis","enrollment":918},{"nctId":"NCT06085079","phase":"PHASE4","title":"Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study","status":"UNKNOWN","sponsor":"Massachusetts Eye Research and Surgery Institution","startDate":"2022-06-01","conditions":"Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate","enrollment":20},{"nctId":"NCT05894707","phase":"PHASE1","title":"Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2023-06","conditions":"Autoimmune Disease","enrollment":32},{"nctId":"NCT02144857","phase":"PHASE4","title":"Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis","status":"UNKNOWN","sponsor":"University of Athens","startDate":"2014-05-30","conditions":"Psoriasis","enrollment":200},{"nctId":"NCT05162937","phase":"PHASE2","title":"to Evaluate the Preliminary Efficacy and Safety of GR1501 Injection in Patients With Active Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2020-09-07","conditions":"Axial Spondyloarthritis","enrollment":160},{"nctId":"NCT05196477","phase":"","title":"Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2021-07-14","conditions":"COVID-19","enrollment":3087},{"nctId":"NCT05344248","phase":"PHASE1, PHASE2","title":"Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2021-01-20","conditions":"Moderate to Severe Psoriasis","enrollment":183},{"nctId":"NCT05604898","phase":"PHASE2","title":"A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis","status":"UNKNOWN","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2021-04-01","conditions":"Psoriasis","enrollment":139},{"nctId":"NCT03031782","phase":"PHASE3","title":"Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-05-23","conditions":"Juvenile Psoriatic Arthritis, Enthesitis-related Arthritis","enrollment":86},{"nctId":"NCT05242588","phase":"PHASE2","title":"Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA","status":"UNKNOWN","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2022-01-26","conditions":"Non-radiographic Axial Spondyloarthritis","enrollment":120},{"nctId":"NCT03111992","phase":"PHASE1","title":"Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-12-18","conditions":"Multiple Myeloma","enrollment":26},{"nctId":"NCT05212051","phase":"PHASE2","title":"Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active AS","status":"UNKNOWN","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2021-12-10","conditions":"Active Ankylosing Spondylitis","enrollment":120},{"nctId":"NCT02662985","phase":"PHASE3","title":"Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-08-22","conditions":"Psoriatic Arthritis","enrollment":166},{"nctId":"NCT02763111","phase":"PHASE2","title":"Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Biocad","startDate":"2016-09","conditions":"Ankylosing Spondylitis","enrollment":88},{"nctId":"NCT05060120","phase":"","title":"Biomarker Panel in Ovarian Torsion","status":"UNKNOWN","sponsor":"Assuta Ashdod Hospital","startDate":"2021-09-12","conditions":"Ovary Torsion, Adnexal Torsion","enrollment":20},{"nctId":"NCT03136861","phase":"PHASE3","title":"SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-06-30","conditions":"Spondyloarthritis","enrollment":383},{"nctId":"NCT03041038","phase":"PHASE2","title":"The Efficacy and Safety of Secukinumab in Patients With Ichthyoses","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2016-12","conditions":"Ichthyosis, Autosomal Recessive Congenital Ichthyosis, Lamellar Ichthyosis","enrollment":20},{"nctId":"NCT03384745","phase":"PHASE2","title":"A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis","status":"COMPLETED","sponsor":"Bond Avillion 2 Development LP","startDate":"2018-07-31","conditions":"Psoriasis","enrollment":313},{"nctId":"NCT01109940","phase":"PHASE2","title":"Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-04","conditions":"Ankylosing Spondylitis","enrollment":39},{"nctId":"NCT01169844","phase":"PHASE2","title":"Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-06","conditions":"Psoriatic Arthritis","enrollment":28},{"nctId":"NCT02762994","phase":"PHASE2","title":"International Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Biocad","startDate":"2016-06","conditions":"Psoriasis","enrollment":120},{"nctId":"NCT02380287","phase":"PHASE1","title":"First-in-human Study to Evaluate Safety, Tolerability and Pharmacokinetics of Various Doses of BCD-085 in Healthy Subjects","status":"COMPLETED","sponsor":"Biocad","startDate":"2015-03","conditions":"Healthy","enrollment":22},{"nctId":"NCT02721966","phase":"PHASE3","title":"Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-10-03","conditions":"Axial Psoratic Arthritis","enrollment":503},{"nctId":"NCT04367441","phase":"PHASE1","title":"Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects","status":"UNKNOWN","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2019-11-25","conditions":"Moderate to Severe Plaque Psoriasis","enrollment":62},{"nctId":"NCT02404350","phase":"PHASE3","title":"Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-08-31","conditions":"Psoriatic Arthritis","enrollment":997},{"nctId":"NCT04220073","phase":"PHASE1","title":"Phase I Study of Comparing Single Dose JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) With Placebo in Tolerability, Safety, Immunogenicity and Pharmacokinetic in Healthy Volunteers","status":"UNKNOWN","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2020-01-05","conditions":"Tolerability, Safety, Immunogenicity and Pharmacokinetic of JS005","enrollment":40},{"nctId":"NCT01892436","phase":"PHASE3","title":"Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-09-30","conditions":"Psoriatic Arthritis","enrollment":460},{"nctId":"NCT03910803","phase":"PHASE2","title":"Treatment of Moderate Hidradenitis Suppurativa","status":"UNKNOWN","sponsor":"Florida Academic Dermatology Centers","startDate":"2019-05-01","conditions":"Hidradenitis Suppurativa","enrollment":20},{"nctId":"NCT02008916","phase":"PHASE3","title":"16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-01-14","conditions":"Spondylitis, Ankylosing","enrollment":226},{"nctId":"NCT01544595","phase":"PHASE3","title":"Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-06-19","conditions":"Moderate to Severe Plaque-type Psoriasis","enrollment":1147},{"nctId":"NCT01377012","phase":"PHASE3","title":"Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-08-30","conditions":"Rheumatoid Arthritis","enrollment":637},{"nctId":"NCT02835716","phase":"","title":"Pre-Clinical (Alzheimers) Diagnosis PCD = Optimum Outcomes OO","status":"UNKNOWN","sponsor":"Millennium Magnetic Technologies, LLC","startDate":"2016-09","conditions":"Alzheimer Disease","enrollment":150},{"nctId":"NCT01770379","phase":"PHASE3","title":"Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10","conditions":"Rheumatoid Arthritis","enrollment":242},{"nctId":"NCT01350804","phase":"PHASE3","title":"Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-09","conditions":"Rheumatoid Arthritis","enrollment":551},{"nctId":"NCT01433250","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-02","conditions":"Multiple Sclerosis","enrollment":39},{"nctId":"NCT02243787","phase":"PHASE1, PHASE2","title":"Safety and Tolerability Study of COVA322 in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis","status":"TERMINATED","sponsor":"Covagen","startDate":"2014-04","conditions":"Plaque Psoriasis","enrollment":24},{"nctId":"NCT00809159","phase":"PHASE2","title":"Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-03","conditions":"Ankylosing Spondylitis","enrollment":60},{"nctId":"NCT00809614","phase":"PHASE2","title":"Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-03","conditions":"Psoriatic Arthritis","enrollment":42},{"nctId":"NCT01426789","phase":"PHASE2","title":"A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-08","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT02144272","phase":"PHASE1","title":"Safety Study to Evaluate LY3114062 in Participants With Inflammatory Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-06","conditions":"Inflammatory Arthritis","enrollment":41},{"nctId":"NCT00669942","phase":"PHASE1, PHASE2","title":"Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-12","conditions":"Rheumatoid Arthritis","enrollment":104},{"nctId":"NCT01359943","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-10","conditions":"Rheumatoid Arthritis","enrollment":221}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":131,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"IL-17A antibody","genericName":"IL-17A antibody","companyName":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","companyId":"genrix-shanghai-biopharmaceutical-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"IL-17A antibody targets the IL-17A receptor Used for Psoriasis, Plaque psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}